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OBJECTIVES: In recent years, well-differentiated carcinomas of the thyroid have been stratified into
low-risk and high-risk groups. The pattern of thyroid cancer in India is different from that seen in the
West. Moreover, patients present with more advanced stages of the disease. Our aim was to develop
protocols for the management of well-differentiated thyroid cancer, based on the analysis of our data
and our experience.
METHODS: Cases of thyroid carcinoma, which were surgically treated at the Tata Memorial
Hospital during 1970–85, were studied. The survival curves were plotted according to the Kaplan-Meier
method. Univariate analysis was done using the log rank test. The prognostic factors analyzed were age,
sex, tumour size, extra-thyroid extension, distant metastases and lymph node metastases. Multivariate
analysis using the Cox regression model was performed. Analyses were separate for follicular and
papillary carcinomas.
RESULTS: Four hundred and seventeen cases were entered in the study, of which 198 were follicular
and 219 were papillary. Based on the evidence derived from this study, we stratified our cases into low-
and high-risk groups. The low-risk group consisted of patients below 40 years of age, nodules smaller
than 5 cm, absence of extra-thyroidal spread and absence of distant metastases. For follicular
carcinoma, the low-risk group had 100% survival at 15 years, compared with 40% for the high-risk
group. (p < 0.001). For papillary carcinomas, the survival at 15 years was 95% for the low-risk group
and 40% for the high-risk group (p < 0.001).
CONCLUSIONS: We recommend lobectomy for the low-risk group, and total thyroidectomy for the
high-risk group and for cases with lymph node metastases. In the latter, total thyroidectomy facilitates
the use of 131I. (Asian J Surg 2002;25(4):319–24)
INTRODUCTION
The choice of treatment for well-differentiated carci-
noma (WDC) of the thyroid has remained controversial
for several decades. This is unfortunate because WDC
tends to occur in the young, particularly in women, and
treatment of which is compatible with several years of
survival. Cosmetic and functional effects of treatment are
important considerations. At the same time, inadequate
treatment is associated with recurrence and compromises
survival. One school of thought advocates total
thyroidectomy or its variants, such as near total
thyroidectomy, ipsilateral total lobectomy, and
contralateral subtotal lobectomy. The essential feature is
the ablation of all contralateral and functional thyroid
tissue. In contrast, the alternative is a total lobectomy with
removal of the isthmus. Strong views are held by both
groups, and are supported by various facts and figures.
In recent years, an attempt has been made to identify
various prognostic factors that would help to divide these
cases into low-risk and high-risk groups. These studies
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have been undertaken mainly for papillary carcinomas,
as they make up the dominant group of thyroid WDCs
in the USA.1 The pattern of thyroid cancer varies
geographically, depending on iodine levels in the diet.
Our objective was to evolve protocols for the management
of WDC of the thyroid that is suitable to our country and
based on our experience. We, therefore, undertook a
retrospective analysis of our data on thyroid cancer.
PATIENTS AND METHODS
We undertook a retrospective analysis of WDC of the
thyroid treated by definitive surgery at Tata Memorial
Hospital for the 15-year period from 1970 to 1985. The
cases included those that were referred to us per primum
and those that underwent revision or completion thyroid-
ectomy at our hospital. All relevant case data for thyroid
WDC, including histopathology slides, were reviewed
by an experienced pathologist at our institute. We also
reviewed our data on patients with WDC of the thyroid
with lymph node metastases treated with surgery followed
by 131Iodine (131I) therapy. This helped us to evolve a
protocol for the management of cases with lymph node
metastases.
Papillary carcinomas were grouped as follows:
1) pure papillary carcinoma, 2) papillary carcinoma with
follicular elements, or 3) follicular variant of papillary
carcinoma. Follicular carcinomas were divided as follows:
1) pure follicular carcinoma, or 2) Hürthle cell carcinoma.
All the patients underwent a high-dose 131I scan 4 to
6 weeks postoperatively. An ablation dose of 131I was
given if there was residual thyroid tissue (more than 5%
uptake) or metastatic disease that picked up the isotope.
Patients were carefully monitored, and their survival was
assessed by Kaplan-Meier analysis.
The following factors were tested for prognostic
significance: 1) age, 2) sex, 3) size of the tumour,
4) extrathyroid spread, 5) systemic metastases and
6) lymph node metastases. Univariate analysis was done
using the log-rank test and multivariate analysis using
the Cox regression model. For the purpose of this study,
we defined age groups as those who were ≤ 40 years, or
> 40 years, and tumour size was divided into those ≤ 5 cm
or > 5 cm. Extra-thyroid spread was defined as the
presence of gross involvement of tissue outside the
capsule of the thyroid gland, involving structures such as
strap muscles, trachea, oesophagus, or the tracheo-
oesophageal groove. Systemic metastases were seen
usually in the lungs or bone. Lymph node metastases
were ipsilateral, contralateral, bilateral, or present in the
central compartment. As a matter of policy, we have
been performing near-total or total thyroidectomy for
these cases. Gross or microscopic invasion of the tumour
capsule was not studied as a prognostic factor, because
microscopic capsular invasion is one of the criteria used
to determine malignancy of a follicular lesion. Grading of
the follicular lesion and other features, such as DNA
ploidy, were not analyzed for their prognostic significance.
RESULTS
Four hundred and seventeen cases of WDC were
studied. Of these, 219 were papillary and 198 were of
the follicular type. The youngest patient was 6 years old
and the oldest, 83 years. There was a slight female
preponderance, the M:F ratio being 1:1.5. Figure 1 shows
the age distribution in the two groups. Papillary
carcinomas are more prevalent at a younger age and
follicular carcinoma tends to occur in the elderly.
Follicular carcinoma
Table 1 is a summary of univariate analysis of survival
of patients with follicular carcinoma, according to the
various factors of possible prognostic significance. The
most important factor was the age of the patient at the
time of presentation. Patients ≤ 40 years of age had a 98%
survival at 15 years compared with 40% survival for
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Figure 1. Age distribution of cases of follicular and papil-
lary carcinoma.
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Table 1. Follicular carcinoma — univariate analysis of survival, according to host and tumour factors
Variables No. of cases Statistical significance
Age ≤ 40 years 78
> 40 years 120 p < 0.001
Sex Males 74
Females 124 p = 0.94 NS
Tumour size ≤ 5 cm 131
> 5 cm 67 p = 0.003
Extra-thyroidal spread Present 12
Absent 186 p = 0.94 NS
Distant metastases Present 52
Absent 146 p < 0.001
Lymph node metastases Present 27
Absent 171 p = 0.023
Table 2. Papillary carcinoma, univariate analysis of survival, according to host and tumour factors
Variables No. of cases Statistical significance
Age ≤ 40 years 122
> 40 years 97 p < 0.001
Sex Males 94
Females 125 p = 0.14 NS
Tumour size ≤ 5 cm 181
> 5 cm 38 p < 0.001
Extra-thyroidal spread Present 44
Absent 175 p < 0.001
Distant metastases Present 13
Absent 206 p = 0.0243
Lymph node metastases Present 56
Absent 163 p = 0.48 NS
NS = not significant.
those older than 40 years. There was no difference in
survival between men and women. The effect of extra-
thyroid extension could not be accurately assessed, as
only 12 patients had extra-thyroidal spread compared to
186 cases without extra-thyroidal spread. Patients with
distant metastases distinctly fared worse. There were 27
cases with lymph node metastases associated with poorer
survival. This was surprising, because lymph node
metastasis was not expected to have any prognostic
significance in WDC of the thyroid.
Papillary carcinoma
Table 2 summarizes our results of univariate analysis
of patients with papillary carcinoma, according to the
various factors of possible prognostic significance. There
NS = not significant.
were 122 cases ≤ 40 years of age who had 95% survival
compared to 40% survival of 97 patients over the age of
40. Patients with extra-thyroidal spread distinctly fared
worse than patients without extra-thyroidal spread. Sex
of the patient, again, was not a significant factor. There
was no significant difference in survival between patients
with or without lymph node metastases. Significant
prognostic factors were the size of the tumour and distant
metastases.
Overall analysis
Survival in patients with lymph node metastases is
summarized in Table 3. The younger age group (those
below ≤ 40 years of age) had a higher chance of survival.
Figure 2 compares survival according to histological
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Table 4. Multivariate analysis of the factors using Cox
regression model
Variable p value
Age < 0.0000*
Sex 0.4180
Tumour Size 0.0307*
Histology 0.9861
Nodal metastases 0.9824
Extrathyroidal spread 0.0009*
Systemic metastases 0.0011*
*Independent, significant variable.
type. Follicular carcinomas fared worse than papillary
carcinomas (p = 0.034). The proportion of patients in the
younger age group (≤ 40 years) was higher in papillary
carcinoma than in follicular carcinoma. Using the Cox
regression model, a multivariate analysis was performed
in order to evaluate the above parameters (Table 4). We
found that the only parameters that were independently
significant were: age, size, extra-thyroidal spread and
systemic metastases. The sex of the patient, lymph node
metastases and histological type did not affect survival.
Based on our experience and the classifications
available in the literature, we considered the following
parameters to be favourable : 1) age less or equal to
40 years, 2) tumour size less than 5 cm, 3) no extra-
thyroidal spread and 4) no systemic metastases.
We stratified the cases into low-risk and high-risk
groups. In the low-risk group, all four parameters were
“favourable”; in the high-risk group, one or more param-
eters were “unfavourable”. To elaborate, a case was
considered high-risk even if only one of the following
factors was present: 1) age more than 40 years, 2) nodule
size larger than 5 cm, 3) extra-thyroidal spread, or
4) distant metastases.
Figure 3 compares the survival between the low-risk
and high-risk groups with follicular carcinoma. In cases
of follicular carcinoma, only 54 patients were in the low-
risk group, compared with 144 in the high-risk group. At
15 years, the survival rate was 100% in the low-risk group
as compared to 40% in the high-risk group (p < 0.001).
Figure 4 shows the survival rate according to risk categories
in papillary carcinoma. There were 90 cases in the low-
Table 3. Survival with lymph node metastases (n = 83)
Age group (years) No. of cases Survivors Percentage
≤ 40 46 42 91.3
> 40 37 24 64.8
p =  0.003
Figure 2. Histological type and survival.
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Figure 3. Follicular carcinoma – risk groups and survival.
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risk group, with 95% survival at 15 years, and 129 cases
in the high-risk group with 40% survival (p < .001). A total
of only 34.5% of WDCs were in the low-risk group.
DISCUSSION
One of the early attempts to identify the prognostic
factors for thyroid carcinomas was reported in 1979 by
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the EORTC Thyroid Cancer Cooperative Group.2 They
considered age, sex, histological type, distant metastases
and lymph node metastases, local extent of disease as
important prognostic factors. They developed a scoring
system (based on a multivariate analysis) and stratified
their cases into six groups.
Hay et al from the Mayo Clinic, first came up with the
AGES scoring system.3 AGES is the acronym for age,
grade, extra-thyroidal spread, and size. Age and size
were continuous variables. At 25 years, the low-risk
group had a 2% mortality, compared with 46% for the
high-risk group. They reported the scoring system as
applicable only to papillary carcinomas. In that study,
86% were in the low-risk and 14% were in the high-risk
group. It was later found that the pathologists were
reluctant to grade papillary carcinomas; hence, this
factor was omitted. In 1993, the Mayo Clinic proposed a
new set of prognostic parameters, called MACIS
(metastases, age, completeness of resection, invasion
and size).4 In the low-risk group, comprising 82% of their
cases, the 20-year mortality was 1%. Again, they applied
the scoring system only to papillary carcinomas.
Cady and the Lahey Clinic group evolved the AMES
system (age, distant metastases, size of lesion, extra-
thyroid involvement).5 They applied their scoring system
to both papillary and follicular carcinomas. Of 310 cases
reported for the period of 1961–1980, 76 (26%) were
follicular. It is not clear from the data how many follicular
carcinomas were in the low-risk group. Mortality in
the low-risk group was 1.8%, compared to 46% in the
high-risk group. Age was considered a very important
parameter, and the cut-off point was 40 years in men, and
50 years in women (there is no explanation for having
separate cut-off points at different ages for men and
women). Another feature observed by both the Mayo
Clinic and the Lahey Clinic groups is that metastatic
lymph nodes were of no prognostic significance. Shah
et al from Memorial Sloan-Kettering Cancer Center,
New York, identified age, histological type, size, distant
metastases and extra-thyroidal spread as significant
variables.6 In their series of 931 cases, there were 200
cases (21.41%) of follicular carcinoma. In their experience,
follicular carcinoma had a worse prognosis.
In our study, follicular carcinoma accounted for 48%
of all thyroid WDC cases. This is very high, when
compared with 26% in the report by Cady and 21% in the
report by Shah et al.5,6 Follicular carcinoma is also
believed to have a worse prognosis than papillary
carcinoma. It has a greater propensity for systemic
metastases and responds better to radio-iodine therapy.
For this reason, we decided to analyze the data separately
for papillary and follicular carcinomas. In a multivariate
analysis for all WDC in our study, we found age, size,
extra-thyroidal spread and systemic metastases to
be significant variables, whereas histological type, sex
of the patient and lymph node metastases had no prog-
nostic value.
Taking into consideration our results in both
histological subtypes, we have adopted a policy of strati-
fying the cases into low-risk and high-risk groups. The
low-risk group comprises patients who satisfy the following
criteria: 1) age ≤ 40 years, 2) nodule size ≤ 5cm, 3) no
extra-thyroid spread and 4) no distant metastases. All
other cases with one or more unfavourable variable(s) are
assigned to the high-risk group. We have not adopted any
scoring system. In a clinical situation with extra-thyroidal
spread or metastases, we will perform a total or near-total
thyroidectomy. The most important single factor to emerge
in all of the studies is importance of age as a prognostic
factor—a more aggressive approach is justified in a
patient older than 40 years. It is pragmatic to have a
uniform system of prognostication for both types of WDC
of the thyroid.
We found that 65.5% of our cases were in the
high-risk group, as compared to 11% in the Lahey Clinic,
and 14% in the Mayo Clinic series. We also have not
evaluated other factors, such as grading or nuclear ploidy
or data that can be obtained from flow cytometry,
for their prognostic significance. The variables that weFigure 4. Papillary carcinoma – risk groups and survival.
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Table 5. Incidence of relapse in patients presenting with nodal metastases treated with 131I therapy (n = 442)
Type of surgery Relapse rate Local recurrence Distant metastases
Total thyroidectomy with RND/MND 44/395 33 11
n = 395 (11.1%) (75%) (25%)
Lobectomy with RND/MND 18/47 13 5
n = 47 (38.3%) (72.2%) (27.8%)
RDN = radical neck dissection; MND = modified neck dissection.
have taken into consideration are factors in which the
status is available to the surgeon in the intra-operative
stage. Such information can help him or her to decide
the extent of surgery in a given case. Nonetheless, it is
possible that the above-named factors may have
prognostic value.
Lymph node metastases do respond to 131I therapy.
Our experience in this area is well documented. Samuel
and Rajashekharrao reported 442 cases of lymph node
metastases treated with 131l therapy.7 Three hundred and
seventy eight of these cases showed complete response
(85.5%), and 20 (4.5%) showed partial response. In 44
cases (10%), there was no response to radio-iodine
therapy. The relapse rate, both in terms of local recur-
rence and distant metastases, was higher in patients who
underwent partial thyroidectomy than in those who had
undergone total thyroidectomy prior to radio-iodine
therapy (Table 5). Although lymph node metastases have
no prognostic significance, and do not affect long-term
survival, we advocate a total thyroidectomy, which will
permit the use of radio-iodine to effectively destroy the
residual metastatic nodes.
Based on our analysis of the various prognostic factors,
and the results of treatment of metastatic lymph nodes
reported from our institution, we recommend:
1) Total thyroid lobectomy for the low-risk group.
2) Total thyroidectomy in a) the high-risk group and b)
low-risk cases with lymph node metastases. This
facilitates adjuvant treatment with radio-iodine.
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